Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 459 across all filing types
Latest filing 2026-01-07 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2025
Share Issue/Capital Change Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. It does not fit into specific categories like 'Earnings Release' or 'Annual Report' but is a recurring regulatory disclosure mandated by the Exchange Listing Rules. Therefore, it is classified as a Regulatory Filing (RNS).
2026-01-07 English
SUPPLEMENTAL ANNOUNCEMENT
Transaction in Own Shares Classification · 95% confidence The document is a 'Supplemental Announcement' issued by Ocumension Therapeutics regarding share repurchases and treasury shares mentioned in their previously filed Annual Report. It provides additional clarification on the status and intended use of these shares. Since it is a regulatory announcement providing supplementary information to a prior filing rather than a primary financial report, a proxy statement, or a standalone transaction report, it falls under the general regulatory announcement category.
2025-12-19 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2025
Regulatory Filings Classification · 100% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. As it is a recurring regulatory filing detailing share movements and capital structure, it falls under the 'Regulatory Filings' category.
2025-12-04 English
VOLUNTARY ANNOUNCEMENT APPROVAL RECEIVED FOR MARKETING OT-702 IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from Ocumension Therapeutics regarding the NMPA approval for marketing a specific drug (OT-702). It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement (RPA) as it provides substantive business news rather than just announcing the availability of a report. Since it is a general regulatory announcement regarding business operations and product development that does not fall into specific categories like M&A or Director's dealings, it is classified as a general regulatory filing (RNS).
2025-11-26 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2025
Regulatory Filings Classification · 100% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. It does not fit into specific categories like 'Annual Report' or 'Earnings Release' but is a recurring regulatory disclosure mandated by the Exchange Listing Rules. Therefore, it is classified as a Regulatory Filing (RNS).
2025-11-06 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2025
Regulatory Filings Classification · 90% confidence The document is a standardized monthly regulatory return (HKEX Form FF301) filed under Chapter 19B of the HKEX Listing Rules, detailing movements in authorised, issued, treasury shares and share option schemes. It is not an earnings release, annual/interim report, proxy, capital raise announcement, or any management or M&A notice. It is a compliance/regulatory disclosure mandated by the exchange, making it a general regulatory filing. Therefore, it is best classified under Regulatory Filings (RNS).
2025-10-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.